21.03.2019

HOW TO TREAT TBI PATIENTS?

Traumatic Brain Injuries (TBI) are a major healthcare problem worldwide with about 15 million new cases happening every year, predominantly to the male population of working age in low-and middle-income countries. Especially for these countries this not only constitutes a major loss of income for millions of households, it is also a huge financial burden for the healthcare systems.

Interestingly, despite the magnitude of the problem, traumatic brain injury seems to be not a major focus of medical societies, of clinical researchers, also of pharmaceutical companies and this is probably the reason why TBI is called also a “silent epidemy”.

Cooperation with the Academy for Multidisciplinary Neurotraumatology (AMN)

EVER Pharma is one of the few companies engaged in clinical research about TBI and related medical education, especially in the countries where traumatic brain injury occurs. We therefore strongly support the mission and vision of a smaller, not yet well-known medical society, the AMN. The medical professionals who collaborate in this society are dedicated to develop, discuss and implement concepts for optimized care for TBI patients. Different specialists in e.g. Critical Care, Neurosurgery, Neurology, Neuropsychology and Neurorehabilitation are involved in this process.

Between April 11th and 13th the AMN will hold their annual meeting in Cluj, Romania. EVER Pharma supports this convention by encouraging our country organizations to select medical experts interested in this field and passionate about improving patient care for this patient group.

So far this “call to action” has been successful and many experts from various areas of TBI care will join the convention and an ensuing half-day workshop in April 2019. In the workshop participants will exchange knowledge about trauma care internationally, will analyse the gaps in patient treatment and design feasible concepts for improvements in their countries.

Cerebrolysin® and TBI

As the upcoming months and years will reveal new clinical data from Cerebrolysin®, EVER Pharma focuses on TBI to communicate the efficacy and safety of Cerebrolysin®. Please find more information about Cerebrolysin® in TBI here. EVER Pharma will demonstrate to experts in this field that we are one of the few companies engaging in acute and subacute trauma care. So, supporting the AMN is a logical consequence.